EUVIMEDEUVIMED entdecken
Crossref

Characteristic of Immunotherapy Trials in Head and Neck Squamous Cell Carcinoma: 2013–2023

Binbin Xia, Fan Wu, Bin Wei, Qunxing Li, Hsinyu Lin, Peichia Lu, Zhijun Xie, Niu Liu, Jiaying Wu, Jianglong Zhong, Song Fan iD

Oral Diseases · 2025

DOI: 10.1111/odi.15251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oral Diseases, 2025. Verfasst von Binbin Xia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral & Maxillofacial Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Immunotherapy, Squamous Cell Carcinoma of Head and Neck, Clinical Trials as Topic, Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: The General Funds of the National Natural Science Foundation of China, The Joint Funds of the National Natural Science Foundation of China (U21A20381), Fundamental Research Funds for the Central Universities, Sun Yat-sen University (19ykzd20).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This research provides a comprehensive analysis of immunotherapy clinical trials for head and neck squamous cell carcinoma, aiming to enhance future trial designs.

Methods

We analyzed all clinical trials focused on head and neck squamous cell carcinoma immunotherapy registered on ClinicalTrials.gov from January 1st, 2013, to December 31st, 2023, examining general characteristics, methodological features, and types of immunotherapeutic drugs.

Results

The analysis included 727 trials, with 687 interventional (94.50%) and 40 observational (5.50%). Most trials were small‐sized (64.37%), single‐centered (56.67%), non‐blinded (94.76%), and non‐randomized (72.93%). Over half of the trials were conducted in North America (55.71%), but trials in Asia increased significantly in the past 5 years (9.88% vs. 32.38%, p < 0.001). Only 20.63% of completed trials updated outcomes, with most results published 6–12 months after primary completion (55.13%). Immune checkpoint inhibitors were the predominant focus, and neoadjuvant immunotherapy was the main regimen in trials with resectable head and neck squamous cell carcinoma (74.83%).

Conclusions

There has been a gradual increase in clinical trials over the past decade, with most being interventional. Delays or absences in outcome submission were prevalent. Novel immunotherapeutic drugs and treatment regimens are a significant focus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapySquamous Cell Carcinoma of Head and NeckClinical Trials as TopicHead and Neck NeoplasmsHumansImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

ClinicalTrials.govclinical trialimmunotherapyprogrammed cell death protein 1squamous cell carcinoma of head and neck

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oral & Maxillofacial Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

ORCID-Profile: Song Fan

Förderung

  • The General Funds of the National Natural Science Foundation of China
  • The Joint Funds of the National Natural Science Foundation of China (U21A20381)
  • Fundamental Research Funds for the Central Universities, Sun Yat-sen University (19ykzd20)
  • Guangzhou Basic Research Program Jointly Funded by Municipal Schools (Institutes) (202201020367)
  • Guangdong Basic and Applied Basic Research Foundation (2021A1515220138)
  • Guangdong Natural Science Funds for Distinguished Young Scholar (2022B1515020061)
  • Fundamental Research Funds for the Central Universities
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Xia, B., Wu, F., Wei, B., Li, Q., Lin, H., Lu, P., Xie, Z., Liu, N., Wu, J., Zhong, J., & Fan, S. (2025). Characteristic of Immunotherapy Trials in Head and Neck Squamous Cell Carcinoma: 2013–2023. Oral Diseases. https://doi.org/10.1111/odi.15251

Vancouver

Xia B, Wu F, Wei B, Li Q, Lin H, Lu P, et al. Characteristic of Immunotherapy Trials in Head and Neck Squamous Cell Carcinoma: 2013–2023. Oral Diseases. 2025. doi:10.1111/odi.15251

BibTeX
@article{Xia2025,
  author = {Xia, Binbin and Wu, Fan and Wei, Bin and Li, Qunxing and Lin, Hsinyu and Lu, Peichia and Xie, Zhijun and Liu, Niu and Wu, Jiaying and Zhong, Jianglong and Fan, Song},
  title = {Characteristic of Immunotherapy Trials in Head and Neck Squamous Cell Carcinoma: 2013–2023},
  journal = {Oral Diseases},
  year = {2025},
  doi = {10.1111/odi.15251}
}
Kostenlos starten →